Esters of bendamustine are by far more potent cytotoxic agents than the parent compound against human sarcoma and carcinoma cells

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Huber, Stefan ^a   Huettner, Johannes Philip ^a   Hacker, Kristina ^b   Bernhardt, Günther ^a   König, Jörg ^b   Buschauer, Armin ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; BENDAMUSTINE ESTER; CYTOTOXIC AGENT; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 3; PROTEIN P53; UNCLASSIFIED DRUG; ALKYLATING AGENT; ESTER; ORGANIC CATION TRANSPORTER; SOLUTE CARRIER FAMILY 22 (ORGANIC CATION TRANSPORTER), MEMBER 3;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BIOACCUMULATION; CANCER CELL DESTRUCTION; CANCER CELL LINE; CANCER INHIBITION; CARCINOMA CELL; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; EMBRYO; HACAT CELL; HT 29 CELL LINE; HUMAN; HUMAN CELL; IC50; INHIBITION KINETICS; JURKAT CELL LINE; NCI H460 CELL; PROTEIN EXPRESSION; SARCOMA CELL; SK ES 1 CELL; SK MEL3 CELL; ANALOGS AND DERIVATIVES; CARCINOMA; CHEMISTRY; HEK293 CELL LINE; METABOLISM; SARCOMA; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, ALKYLATING; BENDAMUSTINE HYDROCHLORIDE; CARCINOMA; CELL LINE, TUMOR; ESTERS; HEK293 CELLS; HUMANS; ORGANIC CATION TRANSPORT PROTEINS; ORGANIC CATION TRANSPORTER 1; SARCOMA;

EID: 84941242780     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0133743     Document Type: Article

References (61)

1. Ozegowski W, Krebs D. Aminosäureantagonisten. III. ε-[Bis-(β-chloräthyl)-amino-benzimidazolyl-(2)]-propion-bzw.-buttersäuren als potentielle Cytostatika. J Prakt Chem. 1963; 20: 178-186.
2. Ozegowski W, Krebs D. IMET 3393, γ-[1-methyl-5-bis-(β-chloroethyl)-amino-benzimidazolyl-(2)]-butyric acid hydrochloride, a new cytostatic agent from among the series of benzimidazole mustard compounds. Zentralbl Pharm. 1971; 110: 1013-1019.
3. Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol. 2009; 27: 1492-1501. doi: 10.1200/JCO.2008.18.7252 PMID: 19224851
4. Kalaycio M. Bendamustine: a new look at an old drug. Cancer. 2009; 115: 473-479. doi: 10.1002/cncr. 24057 PMID: 19117340
5. Tageja N, Nagi J. Bendamustine: something old, something new. Cancer Chemother Pharmacol. 2010; 66: 413-423. doi: 10.1007/s00280-010-1317-x PMID: 20376452
6. Leoni LM. Bendamustine: rescue of an effective antineoplastic agent from the mid-twentieth century. Semin Hematol. 2011; 48 Suppl 1: S4-11. doi: 10.1053/j.seminhematol.2011.03.002 PMID: 21530771
7. Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Hematology. 2013: 138-150.
8. Knauf WU, Lissitchkov T, Aldaoud A, Liberati AM, Loscertales J, Herbrecht R, et al. Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. Br J Haematol. 2012; 159: 67-77. doi: 10.1111/bjh. 12000 PMID: 22861163
9. Gil L, Kazmierczak M, Kroll-Balcerzak R, Komarnicki M. Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma. Med Oncol. 2014; 31: 944. doi: 10.1007/s12032-014-0944-1 PMID: 24752517
10. Pönisch W, Holzvogt B, Plötze M, Andrea M, Bourgeois M, Heyn S, et al. Bendamustine and prednisone in combination with bortezomib (BPV) in the treatment of patients with newly diagnosed/untreated multiple myeloma. J Cancer Res Clin Oncol. 2014; 140: 1947-1956. doi: 10.1007/s00432-014-1737-9 PMID: 24942335
11. Pönisch W, Mitrou PS, Merkle K, Herold M, Assmann M, Wilhelm G, et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone-a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol. 2006; 132: 205-212. PMID: 16402269
12. Cheson BD, Friedberg JW, Kahl BS, Van der Jagt RH, Tremmel L. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2010; 10: 452-457. doi: 10.3816/CLML.2010.n.079 PMID: 21189660
13. Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer. 2010; 116: 106-114. doi: 10.1002/cncr.24714 PMID: 19890959
14. Ludwig H, Kasparu H, Leitgeb C, Rauch E, Linkesch W, Zojer N, et al. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood. 2014; 123: 985-991. doi: 10.1182/blood-2013-08-521468 PMID: 24227817
15. Eichbaum MH, Schuetz F, Khbeis T, Lauschner I, Foerster F, Sohn C, et al. Weekly administration of bendamustine as salvage therapy in metastatic breast cancer: final results of a phase II study. Anticancer Drugs. 2007; 18: 963-968. PMID: 17667603
16. Lammers PE, Shyr Y, Li CI, Hutchison AS, Sandler A, Carbone DP, et al. Phase II study of bendamustine in relapsed chemotherapy sensitive or resistant small-cell lung cancer. J Thorac Oncol. 2014; 9: 559-562. doi: 10.1097/JTO.0000000000000079 PMID: 24736081
17. Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood. 2011; 117: 2807-2812. doi: 10.1182/blood-2010-11-314708 PMID: 21239695
18. Lentzsch S. Bendamustine: the remedy that came in from the cold. Blood. 2014; 123: 948-950. doi: 10.1182/blood-2013-12-539817 PMID: 24526773
19. Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol. 2005; 23: 3383-3389. PMID: 15908650
20. Rummel MJ, Chow KU, Hoelzer D, Mitrou PS, Weidmann E. In vitro studies with bendamustine: enhanced activity in combination with rituximab. Semin Oncol. 2002; 29: 12-14.
21. Surget S, Lemieux-Blanchard E, Maiga S, Descamps G, Le Gouill S, Moreau P, et al. Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other. Leuk Lymphoma. 2014; 55: 2165-2173. doi: 10.3109/10428194.2013.871277 PMID: 24308434
22. Gaul L, Mandl-Weber S, Baumann P, Emmerich B, Schmidmaier R. Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways. J Cancer Res Clin Oncol. 2008; 134: 245-253. PMID: 17653574
23. Cives M, Ciavarella S, Rizzo FM, De Matteo M, Dammacco F, Silvestris F. Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe. Cell Signal. 2013; 25: 1108-1117. doi: 10.1016/j.cellsig.2013.01.020 PMID: 23380051
24. Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbeil J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008; 14: 309-317. doi: 10.1158/1078-0432.CCR-07-1061 PMID: 18172283
25. Colledge J. Solid dosage forms of bendamustine. Patent WO2010063476. 2010.Referenced in: Chem Abstr 153:70374.
26. Colledge J. Oral dosage forms of bendamustine. Patent WO2010063493. 2010.Referenced in: Chem Abstr 153:21223.
27. Labell RY, Patel PR. Oral formulations of bendamustine for cancer treatment. Patent WO2010126676. 2010.Referenced in: Chem Abstr 153:589513.
28. Bakale RP, Brown PD, Chen J, Drager AS, Labell RY, McKean RE, et al. Preparation of bendamustine esters and bendamustine amides and their use for the treatment of cancer. Patent WO2014075035A1. 2014. Referenced in: Chem Abstr 160:723974.
29. Pencheva I, Bogomilova A, Koseva N, Obreshkova D, Troev K. HPLC study on the stability of bendamustine hydrochloride immobilized onto polyphosphoesters. J Pharm Biomed Anal. 2008; 48: 1143-1150. doi: 10.1016/j.jpba.2008.09.001 PMID: 18926656
30. Scutaru AM, Wenzel M, Scheffler H, Wolber G, Gust R. Optimization of the N-lost drugs melphalan and bendamustine: synthesis and cytotoxicity of a new set of dendrimer-drug conjugates as tumor therapeutic agents. Bioconjug Chem. 2010; 21: 1728-1743. doi: 10.1021/bc900453f PMID: 20849062
31. Schickaneder H, Buschauer A, Bernhardt G, Schickaneder C, Limmert M, Huber S. Esters of bendamustine and related compounds, and medical use thereof. Patent EP2656843. 2013. Referenced in: Chem Abstr 159:691800.
32. Gust R, Krauser R. Investigations on the Stability of Bendamustin, a Cytostatic Agent of the Nitrogen Mustard Type, I. Synthesis, Isolation, and Characterization of Reference Substances. Monatsh Chem. 1997; 128: 291-299.
33. Werner W, Letsch G, Ihn W, Sohr R, Preiss R. [Synthesis of a potential metabolite of the carcinostatic bendamustin (Cytostasen)]. Pharmazie. 1991; 46: 113-114. PMID: 1852759
34. Huber S, Antoni F, Schickaneder C, Schickaneder H, Bernhardt G, Buschauer A. Stabilities of neutral and basic esters of bendamustine in plasma compared to the parent compound: Kinetic investigations by HPLC. J Pharm Biomed Anal. 2015; 104: 137-143. doi: 10.1016/j.jpba.2014.11.038 PMID: 25499654
35. Bachmakov I, Glaeser H, Fromm MF, König J. Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1. Diabetes. 2008; 57: 1463-1469. doi: 10.2337/db07-1515 PMID: 18314419
36. Seithel A, Eberl S, Singer K, Auge D, Heinkele G, Wolf NB, et al. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab Dispos. 2007; 35: 779-786. PMID: 17296622
37. Solbach TF, Grube M, Fromm MF, Zolk O. Organic cation transporter 3: expression in failing and nonfailing human heart and functional characterization. J Cardiovasc Pharmacol. 2011; 58: 409-417. doi: 10.1097/FJC.0b013e3182270783 PMID: 21697722
38. Reile H, Birnböck H, Bernhardt G, Spruss T, Schönenberger H. Computerized determination of growth kinetic curves and doubling times from cells in microculture. Anal Biochem. 1990; 187: 262-267. PMID: 2382827
39. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65: 55-63. PMID: 6606682
40. Bernhardt G, Reile H, Birnbock H, Spruss T, Schönenberger H. Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity. J Cancer Res Clin Oncol. 1992; 118: 35-43. PMID: 1309532
41. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst. 1991; 83: 757-766. PMID: 2041050
42. Dobretsov GE, Morozova GI, Barenboim GM. [Free energy of the accumulation of a fluorescent cation probe within lymphocyte mitochondria]. Biofizika. 1985; 30: 833-836. PMID: 3876849
43. Pietruck F, Ullrich KJ. Transport interactions of different organic cations during their excretion by the intact rat kidney. Kidney Int. 1995; 47: 1647-1657. PMID: 7643534
44. Rohlicek V, Ullrich KJ. Simple device for continuous measurement of fluorescent anions and cations in the rat kidney in situ. Ren Physiol Biochem. 1994; 17: 57-61. PMID: 7513899
45. Ullrich KJ, Rumrich G. Luminal transport system for choline+ in relation to the other organic cation transport systems in the rat proximal tubule. Kinetics, specificity: alkyl/arylamines, alkylamines with OH, O, SH, NH2, ROCO, RSCO and H2PO4-groups, methylaminostyryl, rhodamine, acridine, phenanthrene and cyanine compounds. Pflugers Arch. 1996; 432: 471-485. PMID: 8766007
46. Ciarimboli G, Struwe K, Arndt P, Gorboulev V, Koepsell H, Schlatter E, et al. Regulation of the human organic cation transporter hOCT1. J Cell Physiol. 2004; 201: 420-428. PMID: 15389554
47. Massmann V, Edemir B, Schlatter E, Al-Monajjed R, Harrach S, Klassen P, et al. The organic cation transporter 3 (OCT3) as molecular target of psychotropic drugs: transport characteristics and acute regulation of cloned murine OCT3. Pflugers Arch. 2014; 466: 517-527. doi: 10.1007/s00424-013-1335-8 PMID: 23982114
48. Zhang L, Schaner ME, Giacomini KM. Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther. 1998; 286: 354-361. PMID: 9655880
49. Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol. 1988; 106: 761-771. PMID: 2450098
50. Hiraoka N, Kikuchi J, Yamauchi T, Koyama D, Wada T, Uesawa M, et al. Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies. PLoS One. 2014; 9: e90675. doi: 10.1371/journal.pone. 0090675 PMID: 24626203
51. Owen JS, Melhem M, Passarell JA, D'Andrea D, Darwish M, Kahl B. Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma. Cancer Chemoth Pharm. 2010; 66: 1039-1049.
52. Preiß S. Untersuchungen zur Pharmakokinetik und Toxizitätsprofil von Bendamustin an Patienten mit eingeschränkter Leberfunktion. PhD Thesis, Charité-Universitätsmedizin 2011. Available: http://www.diss.fu-berlin.de/diss/receive/FUDISS-thesis-000000020028.
53. König J, Müller F, Fromm MF. Transporters and drug-drug interactions: important determinants of drug disposition and effects. Pharmacol Rev. 2013; 65: 944-966. doi: 10.1124/pr.113.007518 PMID: 23686349
54. Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A, et al. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006; 66: 8847-8857. PMID: 16951202
55. More SS, Li S, Yee SW, Chen L, Xu Z, Jablons DM, et al. Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue. Mol Cancer Ther. 2010; 9: 1058-1069. doi: 10.1158/1535-7163.MCT-09-1084 PMID: 20371711
56. White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC, et al. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood. 2006; 108: 697-704. PMID: 16597591
57. Gupta S, Wulf G, Henjakovic M, Koepsell H, Burckhardt G, Hagos Y. Human organic cation transporter 1 is expressed in lymphoma cells and increases susceptibility to irinotecan and paclitaxel. J Pharmacol Exp Ther. 2012; 341: 16-23. doi: 10.1124/jpet.111.190561 PMID: 22202118
58. Yokoo S, Masuda S, Yonezawa A, Terada T, Katsura T, Inui K. Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer. Drug Metab Dispos. 2008; 36: 2299-2306. doi: 10.1124/dmd.108.023168 PMID: 18710896
59. Shnitsar V, Eckardt R, Gupta S, Grottker J, Müller GA, Koepsell H, et al. Expression of human organic cation transporter 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine. Cancer Res. 2009; 69: 1494-1501. doi: 10.1158/0008-5472.CAN-08-2483 PMID: 19190342
60. Ciarimboli G, Ludwig T, Lang D, Pavenstadt H, Koepsell H, Piechota HJ, et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005; 167: 1477-1484. PMID: 16314463
61. Koepsell H. The SLC22 family with transporters of organic cations, anions and zwitterions. Mol Aspects Med. 2013; 34: 413-435. doi: 10.1016/j.mam.2012.10.010 PMID: 23506881